{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"0","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"description":"A responder is defined as a patient who achieves a best response of partial response or complete response on the study. Response rates will be calculated as the percent of evaluable patients who are responders, and confidence intervals will be constructed using the Wilson score interval method. The revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1) was used to determine response and progression in this study, with specific criteria outlined for the different subtypes of tumors (e.g., 2-dimensional measurements for central nervous system (CNS) tumors).","dispersionType":"90% Confidence Interval","groups":[{"description":"Patients receive olaparib PO BID on days 1-28. Cycles repeat every 28 days for 2 years in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Treatment (Olaparib)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 2 years from study entry","title":"Objective Response Rate (Complete Response/Partial Response)","type":"PRIMARY","unitOfMeasure":"percentage of participants"}